Unknown PHASE2 INTERVENTIONAL 1-arm NCT01006681

Vaccination Against Influenza H1N1 in Rheumatic Diseases

Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Immunomodulatory Drugs

Sponsor: Tel-Aviv Sourasky Medical Center

Conditions Influenza Rheumatic Diseases

Interventions Focetria (Monovalent MF59-Adjuvanted vaccine)

Updated 5 times since 2017 Last updated: Nov 2, 2009 Started: Nov 30, 2009 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Influenza and Rheumatic Diseases, this trial is ongoing. The trial is conducted by Tel-Aviv Sourasky Medical Center and has accumulated 5 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tel-Aviv Sourasky Medical Center

Data source: Tel-Aviv Sourasky Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.